Zentalis Pharmaceuticals stock fell 3.96 percent as target doubled

Published on 10/07/2026 at 04:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zentalis Pharmaceuticals stock saw its target move from USD 4.00 to USD 8.00 on October 5, 2026. Its Q2 loss reached USD 0.59 per share versus a USD 0.49 consensus.

ZNTL, US98943L1070, Illustration mit AI erstellt.

Zentalis Pharmaceuticals stock (ISIN US98943L1070) was last at USD 2.67 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, down 3.96 percent. The move followed a fresh analyst reset, with the new target implying a much higher valuation than the latest market price.

Leerink doubles its target

According to Yahoo Finance on October 5, 2026, Leerink Partners assumed coverage with an Outperform rating and raised its price target from USD 4.00 to USD 8.00. The report linked the assessment to azenosertib, Zentalis' investigational WEE1 inhibitor for platinum-resistant ovarian cancer.

The target increase was 100 percent from Leerink's previous USD 4.00 level. Against the USD 2.67 reference price, the USD 8.00 target lies 199.6 percent above the price, a gap that keeps clinical execution at the center of the valuation debate.

Loss keeps the risk visible

MarketBeat reported on October 5, 2026 that Zentalis posted a Q2 2026 loss of USD 0.59 per share, compared with a consensus loss of USD 0.49. The USD 0.10 shortfall shows why the target increase depends on future trial data rather than current earnings power.

The same MarketBeat report listed a Moderate Buy consensus from 10 analysts, with six Buy ratings, three Holds and one Sell. Its average target was USD 7.50, which lies 181.1 percent above the USD 2.67 price.

October data dates matter

Yahoo Finance reported that Zentalis plans to present overall survival data from Part 1b of its DENALI study at the European Society for Medical Oncology Congress on October 23, 2026. A trial-in-progress poster for the Phase 3 ASPENOVA study is scheduled for October 26, 2026.

Those dates create the next measurable test for azenosertib. The stock's USD 2.67 price sits 61.6 percent below its 52-week high of USD 6.95 and 120.7 percent above its USD 1.21 low, leaving the clinical readouts as the clearest near-term valuation reference.

Stock remains below its yearly high

Zentalis Pharmaceuticals stock was last at USD 2.67 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, with a market capitalization of USD 190.1 million and volume of 827,559 shares. The dated market figures show a smaller company valuation than the USD 7.50 analyst consensus target assumes.